| name | glp1-obesity-agent-nv-profile |
| description | Look up drug-specific nausea and vomiting rates across the full generation of GLP-1-based obesity agents — semaglutide 2.4 mg, semaglutide 7.2 mg, CagriSema, tirzepatide, retatrutide, survodutide, oral semaglutide 25/50 mg, and orforglipron — to counsel patients before initiation or to decide which agent to switch to when tolerability is the deciding factor. Use when a clinician asks "how much nausea should I expect on Wegovy vs Zepbound", "retatrutide vs semaglutide tolerability", "CagriSema side effect profile", "orforglipron vs oral semaglutide", or when a patient needs pre-initiation counselling numbers for a specific obesity GLP-1-based agent. Grounded in Alhazmi & le Roux 2026 (Front Endocrinol) with the original pivotal trial sources. |
GLP-1 Obesity Agent — Nausea & Vomiting Profile
Purpose
Give a clinician a single reference with:
- Drug-specific nausea and vomiting rates from pivotal phase 3 trials.
- Weight loss at the highest studied dose to set efficacy expectations.
- Mechanism class so tolerability patterns can be anticipated.
- Counselling headline to use with patients before initiation.
When to Use
- Pre-initiation counselling: "what should I expect in terms of side effects on this drug?"
- Choosing between two agents when tolerability is the deciding factor.
- Deciding which agent to switch to after intolerance of the current one (use together with
glp1-dose-escalation-troubleshooter).
Injectable Obesity Agents
| Agent | Class | Dose / Frequency | Peak weight loss | Nausea | Vomiting |
|---|
| Semaglutide 2.4 mg (Wegovy / Noveltreat) | GLP-1 RA | 2.4 mg once-weekly SC | ~ −16.0% at 68 wks | ~ 58% | ~ 27% |
| Semaglutide 7.2 mg | GLP-1 RA (higher-dose) | 7.2 mg once-weekly SC | −18.7 to −20.7% at 72 wks | 43.7% | 24.8% |
| CagriSema 2.4 mg | Amylin analogue (cagrilintide) + GLP-1 RA | Once-weekly SC | ~ −20% at 68 wks | ~ 55% | ~ 24.7% |
| Tirzepatide 15 mg (Mounjaro / Zepbound) | Dual GIP / GLP-1 RA | 15 mg once-weekly SC | ~ −21% at 72 wks | 30–33% | 10–12% |
| Retatrutide 12 mg | Triple GIP / GLP-1 / glucagon RA | 12 mg once-weekly SC | ~ −29% at 68 wks | Up to 43% | Up to 20.9% |
| Survodutide 4.8 mg | Dual GLP-1 / glucagon RA | 4.8 mg once-weekly SC | ~ −15% at 46 wks | ~ 56% | ~ 27% |
Oral Obesity Agents
| Agent | Class | Dose / Routine | Peak weight loss | Nausea | Vomiting |
|---|
| Oral semaglutide 25 mg | Peptide GLP-1 RA + SNAC | Daily, fasting, strict 30-min wait | ~ −13.6% at week 64 | ~ 47% | ~ 31% |
| Oral semaglutide 50 mg | Peptide GLP-1 RA + SNAC (higher exposure) | Same as 25 mg | ~ −15.1% at week 68 | ~ 52% | ~ 24% |
| Orforglipron 36 mg | Small-molecule GLP-1 RA (non-peptide) | Daily, no fasting | ~ −11.2% at week 36 (sustained to week 72) | ~ 33.7% | ~ 24% |
Pattern Rules — How to Use These Numbers
- Higher exposure → more nausea and vomiting within the same molecule (semaglutide 50 mg > 25 mg; semaglutide 7.2 mg > 2.4 mg).
- GIP addition modestly improves tolerability vs GLP-1 alone — tirzepatide has the lowest vomiting of any high-efficacy injectable (~10–12%).
- Glucagon receptor addition re-introduces nausea/vomiting — survodutide (dual) and retatrutide (triple) have GLP-1-like GI profiles despite GIP in retatrutide.
- Amylin addition (CagriSema) adds weight loss but increases nausea/vomiting compared with semaglutide 2.4 mg alone (central satiety amplification).
- Oral route does not spare the patient — variable plasma concentrations with oral semaglutide can cause more GI AEs than SC; orforglipron has the lowest N/V among orals.
- Weight loss and GI AE intensity are independent — more nausea ≠ more weight loss. Use tolerability, not symptom severity, to guide escalation.
Counselling Headlines
- "About half of patients feel nauseated during titration. Most settle within 2–3 weeks of each new dose. The dose we end up at is the maximum you tolerate — not a number on the label."
- If choosing tirzepatide: "lowest vomiting rate of the high-efficacy injectables — about 1 in 10."
- If choosing semaglutide 2.4 mg: "about 1 in 4 will vomit; most are mild–moderate and settle with slower titration."
- If choosing retatrutide: "largest weight loss but more nausea — plan for a slow escalation and behavioural measures up front."
- If choosing oral semaglutide 50 mg: "needs fasting + 30-min wait; about half will have nausea. Skip a dose → retake the next day; do not double up."
Cross-References
- Dose-titration decisions (grade nausea, extend/hold/step-back/switch) →
glp1-dose-escalation-troubleshooter
- Symptom-specific dietary advice →
glp1-gi-ae-symptom-advisor
- Antiemetics / antidiarrhoeals / laxatives rescue →
glp1-gi-ae-pharmacological-rescue
- Pre-initiation patient counselling →
glp1-gi-ae-patient-education
- Candidacy in special populations (elderly, EDs, GI disease) →
glp1-candidacy-myths-checker
Source
Alhazmi A, le Roux CW. Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. Front Endocrinol 2026;17:1788698. Tables 1 & 2 (pivotal trial sources: STEP 1, STEP UP, OASIS, STEP trial programme, SURPASS/SURMOUNT, triple-agonist phase 2/3, survodutide phase 2, CagriSema phase 3, orforglipron OASIS/ATTAIN).
